Gilead Sciences (GILD) Common Equity (2009 - 2026)
Gilead Sciences (GILD) posted Common Equity of $11.83 billion for Q2 2026, down 39.6% from $19.59 billion a year earlier and down 49.5% from the prior quarter.
Powered by 
Analysis
Gilead Sciences (GILD) Common Equity (2009 - 2026) Analysis & Trends
At the end of FY2025, Gilead Sciences' Common Equity came in at $22.7 billion, up 18.0% from FY2024.
- Annual Common Equity shows a five-year compound annual growth rate of 4.5% (FY2020 to FY2025).
- In prior years, Gilead Sciences' Common Equity was $19.25 billion in FY2024 (-15.4%), $22.75 billion in FY2023 (+7.3%), $21.21 billion in FY2022 (+0.7%) and $21.06 billion in FY2021 (+15.6%).
- The Q2 2026 figure stands as the lowest quarterly Common Equity since Q4 2013.
- On a year-over-year basis, Common Equity increased in five of the last eight quarters, with growth averaging 0.3%.
- The strongest year-over-year quarter for Common Equity in the past five years was Q3 2021, with growth of 22.9%; the weakest was Q2 2026, with a decline of 39.6%.
- According to Business Quant data, Common Equity for the three prior quarters was $23.43 billion (Q1 2026), $22.7 billion (Q4 2025) and $21.54 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Bristol Myers Squibb | 130.49 Bn | 81.76 Bn | 9.25 Bn | 22.32 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.83 Bn |
| Mar 31, 2026 | 23.43 Bn |
| Dec 31, 2025 | 22.70 Bn |
| Sep 30, 2025 | 21.54 Bn |
| Jun 30, 2025 | 19.59 Bn |
| Mar 31, 2025 | 19.08 Bn |
| Dec 31, 2024 | 19.25 Bn |
| Sep 30, 2024 | 18.39 Bn |
| Jun 30, 2024 | 18.20 Bn |
| Mar 31, 2024 | 17.46 Bn |
| Dec 31, 2023 | 22.75 Bn |
| Sep 30, 2023 | 22.24 Bn |
| Jun 30, 2023 | 21.09 Bn |
| Mar 31, 2023 | 20.94 Bn |
| Dec 31, 2022 | 21.21 Bn |
| Sep 30, 2022 | 21.06 Bn |
| Jun 30, 2022 | 20.22 Bn |
| Mar 31, 2022 | 19.92 Bn |
| Dec 31, 2021 | 21.06 Bn |
| Sep 30, 2021 | 21.47 Bn |
API Access
Gilead Sciences Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=GILD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "GILD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=GILD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();